A protein called CD47 that helps damaged cells avoid destruction by the immune system may be contributing to severe cases of Covid-19, researchers suggested in a report. In other news, Gilead Sciences Inc.’s intravenous antiviral drug remdesivir helped keep high-risk Covid-19 patients out of the hospital in a randomized trial.
Data needed to determine the advisability of booster shots of the Moderna Inc. and Johnson & Johnson Covid-19 vaccines is just weeks away, President Joe Biden’s chief medical adviser, Dr. Anthony Fauci, said on Sept. 19.
Eli Lilly said on Sept. 15 the U.S. government bought 388,000 additional doses of the company’s Covid-19 antibody therapy and Regeneron Pharmaceuticals said on Sept. 14 the U.S. government was buying 1.4 million additional doses of the Covid-19 antibody cocktail REGEN-COV., as infections surge due to the fast-spreading Delta variant.
A study of 614 fully vaccinated health workers in India found a “significant” drop in their Covid-fighting antibodies within four months of the first shot.
President Joe Biden on Sept. 9 will present a six-pronged strategy intended to fight the spread of the highly contagious coronavirus Delta variant and increase U.S. Covid-19 vaccinations, the White House said on Sept. 7.
Indian drug developer Hetero received emergency use approval from the country’s health authorities to make a generic version of Roche Holding AG’s Covid-19 drug.
As cases of the Delta variant continue to raise concerns across the United States, a new variant reaches a warning level for the World Health Organization.
Pennsylvania Governor Tom Wolf on Aug. 31 issued a mask mandate for all K-12 school and child care facilities to protect against the spread of Covid-19, three weeks after the Democrat said he would leave the decision to individual districts.
Half of children aged 12 to 17 have received at least their first vaccination dose against Covid-19, and that age group has the fastest growth rate in vaccinations, the White House said on Aug. 27.
U.S. companies are scrambling to boost production of coronavirus tests increasingly in short supply as Covid-19 cases soar and schools and employers revive surveillance programs that will require tens of millions of tests, according to industry executives and state health officials.
